

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : Spermidine
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability of Spermidine in Healthy Males
Details : Spermidine is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
August 30, 2023
Lead Product(s) : Spermidine
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Spermidine
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Metabolic Responses to Spermidine Supplementation.
Details : Spermidine is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
July 15, 2022
Lead Product(s) : Spermidine
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Spermidine
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Usability of an AI for M923 in Subjects With Moderate to Severe RA
Details : M923 is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
March 29, 2016
Lead Product(s) : Spermidine
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Spermidine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : M923 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
February 05, 2016
Lead Product(s) : Spermidine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Spermidine
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
Details : M923 is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
October 21, 2015
Lead Product(s) : Spermidine
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
